Allied Biotech, Inc. currently has a number of projects in progress:

• HIV vaccine research.
  The objective of this project is to develop an HIV TAT protein-based vaccine, in which mutated TAT protein will be expressed in E. coli. The derived vaccine will be used for preventing or curing HIV patients (this project is expected to be finished in one year and submitted to the Chinese FDA for drug approval).
• Screening new drugs against cancer.
  Allied Biotech, Inc. is using fluorescence techniques to identify specific target molecules against three well-characterized tumor-related factors: mdm2, skp2 and efp.
• New protein study.
  We are studying the function of a new protein involved in atopic dermatitis and breast cancer.

© 2003 Allied Biotech, Inc.